Merck KGaA
As of the edition of 20 October 2026, Merck KGaA runs 81 drugs, 23 of them marketed; it is on route A at 29 targets and on route B at 7 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 8 company names in this family.
- Springworks Therapeutics Inc: acquired in 2025; successor Merck KGaA, Darmstadt, Germany
Drugs by status
| Status | Count |
|---|---|
| Marketed | 23 |
| Active | 14 |
| Went quiet | 11 |
| Stopped | 29 |
| Status not established | 4 |
| Total | 81 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Metformin | none listed | 4 |
| Cetuximab | Ended 2016 (computed from the first US licence) | 2 |
| Somatropin | Ended 2003 (orphan exclusivity) | 4 |
| Mitoxantrone | none listed | 1 |
| Avelumab | Ends 2029 (computed from the first US licence) | 1 |
| Progesterone | none listed | 3 |
| Levothyroxine | none listed | 6 |
| Cladribine | none listed | 0 |
| Follitropin alfa | Ended 2009 (computed from the first US licence) | 0 |
| Clomiphene | none listed | 1 |
| Interferon beta-1a | Ended 2008 (computed from the first US licence) | 0 |
| Cetrorelix | none listed | 1 |
| Menotropins | Ended 1987 (computed from the first US licence) | 2 |
| Choriogonadotropin alfa | Ended 2012 (computed from the first US licence) | 0 |
| Nirogacestat | Ends 2039 (patent) | 1 |
| Tepotinib | Ends 2030 (patent) | 1 |
| Mirdametinib | Ends 2041 (patent) | 2 |
| Lutropin alfa | none listed | 0 |
| Atacicept | Ends 2038 (computed from the first US licence) | 2 |
| Hydroxocobalamin | none listed | 0 |
| Cobalamin | none listed | 0 |
| Praziquantel, (r)- | none listed | 0 |
| Sermorelin acetate | none listed | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 29 targets, route B at 7 targets.
All 36 rows on route A or B
In the product36 company-target rows on route A or B; 33 are not shown here, and no score is.
See all 36 targets where Merck KGaA needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 113 trials led
- Lungs and airways: 39 trials led
- Urinary and reproductive: 34 trials led